India, Oct. 15 -- Akari Therapeutics Plc (AKTX), an oncology biotechnology company, outlined its differentiated antibody-drug conjugate (ADC) payload strategy and development priorities in a new CEO Corner segment featuring President and CEO Abizer Gaslightwala.
The company is advancing its lead candidate, AKTX-101, toward planned Phase 1 clinical development in mid-2027.
ADCs are targeted cancer therapies that use antibodies to deliver cytotoxic payloads directly to cancer cells. As ADCs are increasingly used earlier in treatment, resistance and limited options following relapse have highlighted the need for new payload technologies.
Akari's proprietary PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer ce...